-
公开(公告)号：US11045448B2
公开(公告)日：2021-06-29
申请号：US16497856
申请日：2018-03-30
发明人： Shaomeng Wang , Angelo Aguilar , Shilin Xu , Liyue Huang , Jeanne Stuckey , Tianfeng Xu
IPC分类号： A61K31/397 , A61K31/4523 , A61K31/454 , A61K31/4709 , A61K31/5377 , C07D205/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D413/14
摘要： The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
公开(公告)号：US20230357249A1
公开(公告)日：2023-11-09
申请号：US17924242
申请日：2021-05-14
发明人： Shaomeng Wang , Xin Han , Weiguo Xiang , Chong Qin , Tianfeng Xu , Lijie Zhao , Mingliang Wang , Rohan Rej
IPC分类号： C07D487/04 , C07D519/00
CPC分类号： C07D487/04 , C07D519/00
摘要： The present disclosure provides compounds represented by Formula I : A-L-B 1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification, ompounds having Formula I are androgen receptor degraders useful for the treatment of ancer and other diseases.
-
公开(公告)号：US20220380368A1
公开(公告)日：2022-12-01
申请号：US17760786
申请日：2020-09-18
发明人： Shaomeng Wang , Xin Han , Weiguo Xiang , Bukeyan Miao , Chong Qin , Lijie Zhao , Jianfeng Lu , Tianfeng Xu , Chao-Yie Yang
IPC分类号： C07D471/10 , A61P35/00 , A61P13/08
摘要： The present disclosure provides compounds represented by Formula (I) and the salts or solvates thereof, wherein R3a, E, L, A1, B1, X1, X2, Z1, and Z2 are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer and other diseases.
-
公开(公告)号：US20240166647A1
公开(公告)日：2024-05-23
申请号：US18279225
申请日：2022-03-03
发明人： Shaomeng Wang , Tianfeng Xu , Dimin Wu , Zhixiang Chen , Xin Han , Weiguo Xiang , Rohan Rej , Angelo Aguilar , Longchuan Bai
IPC分类号： C07D471/04 , C07D471/14 , C07D487/04 , C07D487/10 , C07D498/04 , C07D498/14
CPC分类号： C07D471/04 , C07D471/14 , C07D487/04 , C07D487/10 , C07D498/04 , C07D498/14
摘要： The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.
-
公开(公告)号：US20190152947A1
公开(公告)日：2019-05-23
申请号：US16098147
申请日：2017-05-02
发明人： Shaomeng Wang , Angelo Aguilar , Ke Zheng , Shilin Xu , Tianfeng Xu , Denzil Bernard , Liyue Huang
IPC分类号： C07D401/14 , A61P35/00 , C07D401/04 , C07D405/04 , C07D211/34
摘要： The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
公开(公告)号：US20230257365A1
公开(公告)日：2023-08-17
申请号：US18012369
申请日：2021-07-09
发明人： Shaomeng Wang , Xin Han , Weiguo Xiang , Chong Qin , Tianfeng Xu , Lijie Zhao
IPC分类号： C07D401/14 , C07D451/06 , C07D451/14 , C07D519/00 , C07D487/04 , C07D487/10 , C07D471/04 , C07D491/08
CPC分类号： C07D401/14 , C07D451/06 , C07D451/14 , C07D519/00 , C07D487/04 , C07D487/10 , C07D471/04 , C07D491/08
摘要： The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for the treatment of cancer and other diseases.
-
公开(公告)号：US20200022953A1
公开(公告)日：2020-01-23
申请号：US16497856
申请日：2018-03-30
发明人： Shaomeng Wang , Angelo Aguilar , Shilin Xu , Liyue Huang , Jeanne Stuckey , Tianfeng Xu
IPC分类号： A61K31/397 , C07D401/14 , C07D401/06 , C07D413/14 , C07D401/12 , C07D205/04 , A61K31/4523 , A61K31/4709 , A61K31/454 , A61K31/5377
摘要： The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
公开(公告)号：US20220081435A1
公开(公告)日：2022-03-17
申请号：US17420421
申请日：2019-12-19
发明人： Shaomeng Wang , Xin Han , Chao Wang , Chong Qin , Weiguo Xiang , Tianfeng Xu , Chao-Yie Yang
IPC分类号： C07D417/14 , A61K47/55 , A61K45/06
摘要： The present disclosure provides compounds represented by Formula (I): A-L-B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.
-
公开(公告)号：US20210198237A1
公开(公告)日：2021-07-01
申请号：US17101323
申请日：2020-11-23
发明人： Shaomeng Wang , Angelo Aguilar , Ke Zheng , Shilin Xu , Tianfeng Xu , Denzil Bernard , Liyue Huang
IPC分类号： C07D401/14 , C07D401/04 , C07D405/04 , C07D211/34 , A61P35/00
摘要： The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
公开(公告)号：US10899738B2
公开(公告)日：2021-01-26
申请号：US16098147
申请日：2017-05-02
发明人： Shaomeng Wang , Angelo Aguilar , Ke Zheng , Shilin Xu , Tianfeng Xu , Denzil Bernard , Liyue Huang
IPC分类号： C07D401/14 , C07D401/04 , C07D405/04 , C07D211/34 , A61P35/00
摘要： The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.035 秒)
